---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-115444"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:45:52.261035+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Iovance updates corporate presentation with Q3 2024 financials and pipeline status

## Summary
- Cash and investments of ~$404M as of Sept 30, 2024; Q3 product revenue of $58.6M.
- FY 2024 product revenue guidance reaffirmed at $160–$165M.
- 56 Authorized Treatment Centers (ATCs) as of Nov 7, 2024; over 140 Amtagvi patients treated.
- More than 250 million U.S. patient lives covered by payer policies.
- Pipeline includes ongoing TILVANCE-301 Phase 3 trial in frontline advanced melanoma.

## SEC filing metadata
- accession: 0001104659-24-115444
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465924115444/0001104659-24-115444-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465924115444/tm2427860d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-115444
- JSON: https://secwatch.observer/filing/0001104659-24-115444.json
- Plain text: https://secwatch.observer/filing/0001104659-24-115444.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.